Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 2/13/2019 |
| Start Date: | January 2013 |
| End Date: | December 2020 |
This research is being done to assess the long term prognosis of patients treated with
ranibizumab for edema due to retinal vein occlusion.
ranibizumab for edema due to retinal vein occlusion.
People treated with ranibizumab for edema due to retinal vein occlusion as part of previous
studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist
at the Wilmer Eye Institute are followed up to assess long term outcomes
studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist
at the Wilmer Eye Institute are followed up to assess long term outcomes
Inclusion Criteria:
- All patients who have been enrolled in the following three trials will be included in
the study:
A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple
Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein
Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal
vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with
intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and
the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach
(RELATE)"
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
